Erratum: Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia

Jo, S; Lee, J H; Mattei, J J; Barrett, D M; Elzen, P van den; Grupp, S A; Reid, G S D; Seif, A E

doi:10.1038/leu.2017.312

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that solid and liquid tumors share immune evasion mechanisms. Studies on B cell precursor (pre-B) ALL mouse models to analyze the cytotoxicity effect of CTLs on non-immunogenic leukemic cells revealed that leukemic blasts, which are not eliminated by the initial immune response, remain in a dormant state during immune surveillance until an immune-evasive clone emerges, which requires a loss of immunogenic antigens for immune escape ( 77 ). In addition, it was proposed that ALL displayed immunological ignorance or immune tolerance (described as poor immunogenic clones that fail to alert the immune sensing mechanisms and avoid immune response) because leukemia cells lack or only a subset of them express relevant co-stimulatory accessory molecules (CD80 and CD87, respectively), showing deficient T cell activation ( 78 , 79 ).…”

Section: Immune Evasion Mechanisms In Allmentioning

confidence: 99%

Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia

et al. 2021

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of the pediatric cases and 40–50% of the adult patients relapse during and after the treatment period. The potential mechanisms that cause relapse involve clonal evolution, innate and acquired chemoresistance, and the ability of ALL cells to escape the immune-suppressive tumor response. Currently, immunotherapy in combination with conventional treatment is used to enhance the immune response against tumor cells, thereby significantly improving the OS in patients with ALL. Therefore, understanding the mechanisms of immune evasion by leukemia cells could be useful for developing novel therapeutic strategies.

show abstract

Section: Immune Evasion Mechanisms In Allmentioning

confidence: 99%